News

Cancer Therapy Advisor2d
T-DXd Plus Pertuzumab Could Be New Standard of Care for Advanced Breast Cancer
T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.
Health And Pharma3d
DESTINY-Breast09: Enhertu-pertuzumab Combo Shows 44% Risk Reduction in HER2+ Breast Cancer
Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...
The American Journal of Managed Care3d
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...
MedPage Today on MSN6d
T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer
Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the ...
The Lancet6d
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
aResearch Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias, Santa Cruz de Tenerife, Spain bGenomics Division, Instituto Tecnológico y de ...